Soft miniature machines demonstrate multimodal actuation and morphology change capabilities in narrow spaces smaller than their dimension. The wirelessly controlled soft‐bodied features make them promising candidates for microrobotic manipulation and targeted operation in a noninvasive manner. Liquid‐bodied machine offers an ultrasoft body with extreme deformability owing to its fluid nature, enabling adaptive navigation with smooth contact with objects and environmental restrictions. Over the last decade of development, significant research progress has been achieved in wirelessly controlling liquid‐bodied machines for diverse manipulation applications. Herein, an overview of the recent research results in magnetic control methods and diverse microrobotic applications of liquid‐bodied machines is provided. Considering the control mechanisms and application challenges, ferrofluid‐based, liquid metal‐based, and liquid marble‐based machines are mainly discussed with a brief discussion on droplet‐based machines. The connection between control methods and applications is highlighted with a detailed analysis of machine–object and machine–environment interactions. The current challenges and research opportunities on liquid‐bodied miniature machines are outlined, aiming at designing intelligent liquid‐bodied machine‐based microrobotic systems and promoting the development of small‐scale robotics.

No abstract

Untethered small-scale machines (USSMs) that can actively adjust their motion, deformation, and collective states in response to external stimuli have gained enormous interest in various manipulation, sensing, and biomedical applications. Because they can be efficiently operated in confined and tortuous environments, USSMs are capable of conducting wireless microrobotic manipulation tasks that tethered machines find hard to achieve. Over the past decade of development, significant research progress has been achieved in designing USSM-based manipulation strategies, which are enabled by investigating machine-object, machine-environment, and machine-machine interactions. This review summarizes the latest developments in USSMs for microrobotic manipulation by utilizing individual machines, coordinating multiple machines, and inducing collective behaviors. Providing recent studies and relevant applications in microrobotic and biomedical areas, we also discuss the challenges and future perspectives facing USSMs-based intelligent manipulation systems to achieve manipulation in complex environments with imaging-guided processes and increasing autonomy levels.

No abstract

Purpose: Thrombus aspiration in ST-elevation myocardial infarction (STEMI) with high thrombus burden did not improve clinical outcomes. The clinical e cacy of bailout use of platelet glycoprotein IIb/IIIa inhibitors (GPIs) in this clinical scenario remains unknown.Methods: We assessed associations between GPI use and in-hospital major bleeds, ischemic events, and mortality among STEMI patients treated with percutaneous coronary intervention (PCI) and thrombus aspiration in a nationwide acute coronary syndrome registry (the Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome project).Results: A total of 5,896 STEMI patients who received thrombus aspiration were identi ed, among which 56.3% received GPI therapy. In a 1-to-1 propensity-score-matched cohort, compared with STEMI patients not treated with GPI, GPI use was associated with a 69% increase in major in-hospital bleeds, with an odds ratio (OR) of 1.69, a 95% con dence interval (CI) of 1.08 to 2.65, and a nonsigni cant reduction in ischemic events (OR: 0.61, 95% CI: 0.36 to 1.06), as well as a neutral effect on mortality (OR: 0.93, 95% CI: 0.55 to 1.58). However, among patients aged < 65 years, GPI use was associated with a reduction in ischemic events (OR: 0.26, 95% CI: 0.08 to 0.77), and no signi cant increase in major bleeds (OR: 1.23, 95% CI: 0.67 to 2.25) was observed.Conclusion: In a nationwide registry, routine use of GPI following thrombus aspiration was not associated with reduced in-hospital ischemic events and mortality, but at the cost of increased major bleeding.However, for patients aged < 65 years, there may be a potential net bene t.